Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab + SOX Following Radiotherapy for Advanced Gastric/GEJ Adenocarcinoma
NCT07502027Phase 4Not yet recruiting
- Sponsor
- Huazhong University of Science and Technology
- Start
- Jun 2026
- Primary completion
- Mar 2028
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 4 trial of iparomlimab, tuvonralimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Huazhong University of Science and Technology. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07502027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07502027.